A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination With Abiraterone in Chemotherapy Naive Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2015
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary) ; Abiraterone acetate; Prednisone
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Sponsors Exelixis
- 19 Feb 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 05 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 03 Dec 2013 New trial record